Kliniken Essen-Mitte

Essen, North Rhine-Westphalia 45136

0 studies enrolling now · 2 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Low-grade Serous Peritoneal Cancer

Studies at this site

• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer — Stopped early